Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Income from Continuing Operations (2016 - 2026)

Ironwood Pharmaceuticals' Income from Continuing Operations history spans 16 years, with the latest figure at 129678000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 178.68% to 129678000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 156048000.0, a 193.9% increase, with the full-year FY2025 number at 155948000.0, up 193.84% from a year prior.
  • Income from Continuing Operations hit 129678000.0 in Q4 2025 for Ironwood Pharmaceuticals, up from 40120000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for IRWD hit a ceiling of 391303000.0 in Q2 2021 and a floor of 1089522000.0 in Q2 2023.
  • Historically, Income from Continuing Operations has averaged 21320750.0 across 5 years, with a median of 37922500.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: crashed 3038.3% in 2023 and later skyrocketed 2846.74% in 2025.
  • Tracing IRWD's Income from Continuing Operations over 5 years: stood at 41346000.0 in 2021, then soared by 177.29% to 114647000.0 in 2022, then tumbled by 235.83% to 155720000.0 in 2023, then fell by 5.84% to 164817000.0 in 2024, then soared by 178.68% to 129678000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for IRWD at 129678000.0 in Q4 2025, 40120000.0 in Q3 2025, and 23622000.0 in Q2 2025.